Verona Pharma is off to a promising start as it launches its first product, Ohtuvayre, a maintenance treatment for chronic obstructive pulmonary disorder (COPD). In 2024, Ohtuvayre generated sales ...

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

In the phase 3 ENHANCE trials, Ohtuvayre was shown to reduce exacerbation rate and risk over 24 weeks in COPD patients, regardless of blood eosinophil levels, compared to placebo, and also improve ...

GlobalData has suggested that Ohtuvayre could have a transformative role to play in the management of COPD patients who are prone to exacerbations, sudden flare-ups in symptoms that signal the ...

Boobalan Pachaiyappan, an analyst from Roth MKM, has initiated a new Buy rating on Verona Pharma (VRNA).Stay Ahead of the Market:Discover ...

Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

Verona Pharma's Ohtuvayre, a novel COPD treatment, achieved $36 million in Q4 sales, indicating strong market interest and unmet need for new therapies. Despite aggressive pricing, Ohtuvayre's ...

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

“2024 was another transformational year for Verona with the approval and US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (“COPD ...